75P Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib + checkpoint inhibitor (CPI) therapy
| Autor: | Huynh, L., Du, S.S., Chang, R., Pi, S., Sundaresan, S., Duh, M.S., Thomaidou, D., Zanotti, G., Zakharia, Y. |
|---|---|
| Zdroj: | In Annals of Oncology December 2021 32 Supplement 7:S1404-S1405 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|